AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business and Scientific Updates AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company dedicated to discovering and developing novel small-molecule therapeutics using its proprietary boron chemistry platform, today announced its financial…
Kezar Life Sciences Provides Third Quarter 2025 Financial and Corporate Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics targeting immune-mediated diseases, announced its financial results for the third quarter ended September 30,…
Arcturus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Corporate Updates Arcturus Therapeutics Holdings Inc. (“Arcturus” or the “Company”) (Nasdaq: ARCT), a commercial-stage messenger RNA (mRNA) medicines company dedicated to developing innovative treatments for liver and respiratory rare…
CuraSen Therapeutics Presents Positive Phase 1 Data Demonstrating Safety, Pharmacokinetics, and Pharmacodynamics of CuraAX (CST-3056) at the 2025 American Autonomic Society International Symposium CuraSen Therapeutics, Inc., a privately held biopharmaceutical company focused on developing novel therapies for neurodegenerative and neuropsychiatric…
Onchilles Pharma Publishes Landmark ELANE Pathway Study, Advances N17350 Toward Clinical Development With New Financing and Strategic Clinical Expertise Onchilles Pharma, a privately held biotechnology company developing a new class of next-generation cytotoxic immunotherapies, has taken major steps toward redefining…
Synthekine Unveils Encouraging Early Clinical Results for STK-012 in Combination Therapy for First-Line PD-L1–Negative Non-Squamous NSCLC at SITC 2025 Synthekine Inc., a biotechnology company advancing a new generation of engineered cytokine therapeutics, released promising initial findings from its Phase 1a/1b…
Mirum Pharmaceuticals Spotlights Advancements in Rare Liver Disease With New Data From LIVMARLI® and Volixibat Programs at AASLD’s The Liver Meeting® 2025 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biotechnology company focused on developing and commercializing therapies for rare and severe…
Biomunex to Present Preclinical Data on MAIT Engager Platform at 2025 SITC Annual Meeting Biomunex Pharmaceuticals, an innovative French biopharmaceutical company advancing the next generation of antibody-based immunotherapies, announced that it will present new preclinical data from its proprietary MAIT…
Mirum Pharmaceuticals Announces Third Quarter 2025 Results and Highlights Strong Commercial Execution, Pipeline Advancement, and Strategic Positioning for 2026–2027 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company dedicated to transforming the treatment landscape for rare liver diseases, announced its financial…
PharmaJet to Showcase Advancements in Intradermal Needle-Free Delivery at ASTMH Annual Meeting PharmaJet®, a leading company focused on transforming injectable delivery through needle-free technology, announced that it will present new results and strategic insights from its intradermal (ID) programs at…
Vertex Pharmaceuticals Reports Robust Third Quarter 2025 Results and Refines Full-Year Outlook as Pipeline Momentum Accelerates Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), a global leader in genetic and transformative medicine, today announced financial results for the third quarter ended September 30,…
PureTech’s Gallop Oncology to Present Promising Phase 1b Data of LYT-200 in Relapsed/Refractory AML at the 2025 ASH Annual Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a biotherapeutics innovator renowned for its hub-and-spoke model that…